Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $31.37, but opened at $32.57. Harrow shares last traded at $34.97, with a volume of 84,110 shares traded.
Analyst Ratings Changes
Several research firms recently weighed in on HROW. BTIG Research initiated coverage on Harrow in a research note on Thursday, June 12th. They issued a "buy" rating and a $62.00 price objective on the stock. HC Wainwright lifted their price target on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th. B. Riley lowered their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. William Blair assumed coverage on shares of Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday. They set an "overweight" rating and a $76.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $63.83.
View Our Latest Stock Analysis on Harrow
Harrow Trading Up 11.3%
The company has a current ratio of 0.91, a quick ratio of 0.85 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -62.37 and a beta of 0.41. The firm's 50-day moving average is $29.03 and its 200 day moving average is $28.82.
Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. The business had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. On average, equities analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Harrow
Institutional investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Harrow by 89.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock worth $2,078,000 after acquiring an additional 29,262 shares during the last quarter. GAMMA Investing LLC increased its position in Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock valued at $1,670,000 after purchasing an additional 6,027 shares during the period. Northern Trust Corp raised its holdings in Harrow by 7.5% during the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after purchasing an additional 22,266 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Harrow by 8.4% in the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock worth $2,900,000 after purchasing an additional 6,690 shares during the period. Institutional investors own 72.76% of the company's stock.
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
